Silo Pharma Inc SILO

Healthcare Biotechnology

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

NDAQ:SILO - Post by User

Silo Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jun 05, 2024 5:45pm

44 Views

Post# 36074038

Silo Pharma Announces $2 Million Registered Direct Offering

JUST IN: $SILO Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic t...SILO - Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

<< Previous

Bullboard Posts

Next >>

Inflation reaches Bank of Canada's 2 per cent target